Martien Van Osch

Martien is Managing Partner, heading the Singapore Office of Forbion and has a leading role across the Forbion Platform and Portfolio.

He was responsible for the exits of PneumRx (sold to BTG in 2015), Circulite (sold to Heartware in 2013) and Pathway (sold to Bayer Medrad in 2011), Impella (sold to Abiomed, Inc. in 2005) and Flowmedica, Inc. (sold to Angiodynamics in 2009). His biopharma experience in the life sciences industry encompasses prior non-executive board positions at Santaris (sold to Roche in 2014) and Acadia (IPO on Nasdaq in 2004). He currently serves as chairman of Staten Biotechnology.

Before co-founding Forbion, Martien was an Investment Director at ABN AMRO Capital Life Sciences. Before joining in 2000 the newly formed life sciences team, he held other positions in ABN AMRO Capital and in ABN AMRO Group Planning and Control (HQ Amsterdam).

Martien has a degree in Econometrics from the Rijksuniversiteit Groningen.